Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population

Executive Summary

Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.

You may also be interested in...



CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth

New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.

Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval

The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel